23rd July 2024

Non-Hodgkin lymphoma

Background of NHL

NHL refers to any lymphoma that is not HL. As such, it encompasses a large and heterogenous group of conditions, only a few of which will be discussed here. NHL can be split into indolent and aggressive lymphomas.

NHL incidence increases with age and there is a male predominance.

There are numerous risk factors including congenital and acquired immunodeficiencies, autoimmune conditions, familial risk and environmental factors (e.g. pesticide exposure). There are also subtype-specific risk factors.

Prognosis is very dependent on subtype. In general, markers of poor prognosis include age >60, raised serum LDH, disease stage III or IV, ≤2 extranodal disease sites and poor performance status.

Presentation and diagnosis of NHL

Indolent (low-grade) lymphomas present insidiously, sometimes with symptoms over months to years. They are often disseminated at presentation and less likely to be curable. Aggressive (high-grade) lymphomas present sub-acutely or acutely with localised rapidly growing lymphadenopathy with or without ‘B’ symptoms but are more likely to be curable.

Painless lymphadenopathy is present in >2/3 of patients at presentation. ‘B’ symptoms are more likely to present in aggressive lymphomas. Hepatosplenomegaly is more common in indolent lymphomas.

As indolent lymphomas may be disseminated at presentation, they may present with extranodal symptoms. Gastrointestinal involvement may cause anorexia, early satiety and vomiting. Central nervous system involvement may cause headaches, focal neurological deficits or seizures.

Definitive diagnosis relies on tissue biopsy, imaging and immunohistochemistry (see above).

Follicular lymphoma

This is an indolent B-cell lymphoma. It is the most common indolent NHL and the second most common NHL. Median age at diagnosis is 65 years. The majority exhibit t(14;18), causing overexpression of the BCL2 oncogene. Lymphadenopathy is the most common presenting complaint; around 70% present with stage IV disease with BM involvement. Early-stage disease may be treated with IFRT. Advanced-stage disease may be treated with active surveillance if asymptomatic or if symptomatic, chemoimmunotherapy (e.g. R-CHOP). Median survival is 10 years.

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)

This is more commonly known as a MALT lymphoma. It is an indolent B-cell lymphoma. Median age of diagnosis is 66 years. MALT lymphomas can occur in any tissue with MALT e.g. stomach, small bowel, lung. They often arise on a background of chronic immune stimulation.

Gastric MALT lymphomas frequently develop following chronic gastritis caused by Helicobacter pylori. Over 90% of patients are H. pylori positive. They can present with dyspepsia, epigastric pain or gastrointestinal bleeding. Diagnosis is made with endoscopy and biopsy. Most patients present with localised disease. First line treatment for local disease in H. pylori positive patients is eradication therapy. In H. pylori negative patients or in H. pylori positive patients not responding to first line therapy, IFRT is used. 5-year survival is >80%.

H. pylori eradication therapy consists of a proton pump inhibitor (PPI) and antibiotics (first line: amoxicillin and clarithromycin/metronidazole; second line: amoxicillin and a tetracycline/quinolone, e.g. levofloxacin).

Diffuse large B-cell lymphoma (DLBCL)

This is an aggressive lymphoma and the most common NHL. Median age of diagnosis is 64 with a slight male predominance. DLBCL can occur de novo or from transformation of a low-grade lymphoma or of CLL (Richter’s transformation). It presents as rapidly progressing stage I or II disease in 50% of cases; extranodal disease is common. Early-stage disease is treated with R-CHOP chemoimmunotherapy +/- IFRT. Advanced-stage disease is treated with R-CHOP.

Mantle cell lymphoma

This is an uncommon, aggressive B-cell lymphoma, although there is a subset of patients who experience a more indolent disease course. Median age of diagnosis is 63 years, and it has a strong male predominance. It is highly associated with t(11;14). Around 70% of patients present with stage IV disease. There is no standardised first-line therapy; conventional chemoimmunotherapy with R-CHOP can be used. Median survival is 3-4 years.

Burkitt lymphoma

This is a highly aggressive B-cell lymphoma. There are three forms of the disease: endemic, sporadic and immunodeficiency associated. All three are clinically similar and dependent on dysregulation of the MYC gene on chromosome 8 through translocations.

• Endemic disease is seen primarily in Africa, presenting with extranodal disease of the jaw/facial bones (most common) or abdominal organs. Peak incidence is 4-7 years; 90% are associated with EBV infection.
• Sporadic disease is seen more in developed nations, usually presenting with abdominal symptoms, but a smaller percentage can present with jaw/facial bone disease. Median age of presentation is 31 years; 30% are associated with EBV infection.
• Immunodeficiency-associated disease is primarily seen in patients with HIV infection but also in other causes of acquired or congenital immunodeficiency.

Adult T-cell leukaemia-lymphoma (ATLL)

This is an aggressive lymphoma caused by chronic infection with human T-lymphotropic virus type 1 (HTLV-1). Incidence is highest where HTLV-1 infection is endemic: islands in southwest Japan, the Caribbean, parts of West Africa and Central and South America. There is often a long latency period of several decades between infection and development of ATLL; median age of diagnosis is 58 years. Median survival is very poor, ranging from months to a year, depending on subtype. Treatment is with combination chemotherapy.

Enteropathy-associated T-cell lymphoma (EATL)

EATL is an aggressive lymphoma highly associated with untreated coeliac disease. Management of coeliac disease with a gluten-free diet prevents development of EATL. Patients present with abdominal pain, often associated with gastrointestinal bleeding, bowel obstruction or perforation.  Treatment is with combination chemotherapy with or without autologous SCT. Overall 5-year survival is 10-20%.